0001104659-22-087229.txt : 20220808 0001104659-22-087229.hdr.sgml : 20220808 20220808161131 ACCESSION NUMBER: 0001104659-22-087229 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220808 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220808 DATE AS OF CHANGE: 20220808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cara Therapeutics, Inc. CENTRAL INDEX KEY: 0001346830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36279 FILM NUMBER: 221144477 BUSINESS ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-406-3700 MAIL ADDRESS: STREET 1: 4 STAMFORD PLAZA STREET 2: 107 ELM STREET 9TH FLOOR CITY: STAMFORD STATE: CT ZIP: 06902 FORMER COMPANY: FORMER CONFORMED NAME: Cara Therapeutics Inc DATE OF NAME CHANGE: 20051213 8-K 1 tm2222475d2_8k.htm FORM 8-K
0001346830 false 0001346830 2022-08-08 2022-08-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) August 8, 2022

  

CARA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36279   75-3175693

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

         

4 Stamford Plaza

107 Elm Street, 9th Floor

Stamford, Connecticut

       06902
 (Address of principal executive offices)       (Zip Code)
         
Registrant's telephone number, including area code (203) 406-3700
         

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

  

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol Name of each exchange on which registered
Common Stock, par value $0.001 per share CARA The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨.

 

 

   

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On August 8, 2022, Cara Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2022. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.

 

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing.

 

Item 9.01.Financial Statements and Exhibits.

 

(d)          Exhibits  

 

Exhibit No.   Description
     
99.1   Press Release dated August 8, 2022
104   Cover page interactive data file (formatted as Inline XBRL)

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

CARA THERAPEUTICS, INC. 

   
  By: /s/ RICHARD MAKARA
    Richard Makara
    Vice President, Head of Accounting & Controller
    (Principal Financial and Accounting Officer)

 

Date: August 8, 2022

 

3 

 

 EX-99.1 2 tm2222475d2_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

Cara Therapeutics Reports Second Quarter 2022 Financial Results

 

– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia® (difelikefalin) –

 

– KOMFORT Phase 2 trial met primary endpoint in notalgia paresthetica, validating potential broad utility of oral difelikefalin across multiple disease categories; FDA meeting expected in 2H 2022 –

 

– Conference call today at 4:30 p.m. ET –

 

STAMFORD, Conn., August 8, 2022 – Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the second quarter ended June 30, 2022.

 

“During the second quarter of 2022, we made great strides toward establishing Cara Therapeutics as the leader in the treatment of chronic pruritus,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. “The early U.S. launch of KORSUVA™ (difelikefalin) injection with our commercial partner Vifor has been progressing as expected, with independent and midsize dialysis organizations driving initial product uptake. We anticipate demand to accelerate in the coming months, driven by large dialysis organizations that started purchasing early in the third quarter.”

 

Mr. Posner continued, “In June 2022, we were pleased to announce positive topline results from our KOMFORT Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of pruritus in patients with notalgia paresthetica. We continue to deliver against our commitments associated with our three strategic priorities both on the commercial and development side of the business thereby driving long-term growth and value creation.”

 

Second Quarter and Recent Developments:

 

KORSUVA Injection: Chronic Kidney Disease-Associated Pruritus: Hemodialysis

 

In April 2022, the Company and its commercial partner, Vifor, launched KORSUVA (difelikefalin) injection in the U.S. for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. KORSUVA injection generated net sales of $16.8 million in the second quarter of 2022, translating into $8 million in profit-sharing revenue for Cara. Wholesalers shipped 1,812 vials driven by independent and midsize dialysis organizations.

 

 

 

 

 

In the second quarter, the Company received the $15 million regulatory milestone payment triggered by the April 2022 European Commission approval of Kapruvia® (difelikefalin) for the treatment of moderate-to-severe pruritus associated with CKD in adult hemodialysis patients. Also in April 2022, Kapruvia was approved in the UK. The Company expects the commercial launches of Kapruvia to commence in certain European markets in the second half of 2022.

 

Oral Difelikefalin: Notalgia Paresthetica

 

In June 2022, the Company announced positive topline results from the KOMFORT Phase 2 multicenter, randomized, double-blind, placebo-controlled, 8-week study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in patients with notalgia paresthetica (NP). The Company has submitted the data for presentation at an upcoming medical meeting and plans to host an R&D Day focused on NP in the third quarter of 2022. In addition, the Company anticipates having a meeting with the U.S. Food and Drug Administration in the second half of 2022 to discuss next steps in the development of oral difelikefalin for the treatment of pruritus in patients with NP.

 

Oral Difelikefalin: Pruritus Associated with Non-Dialysis Dependent Advanced Chronic Kidney Disease

 

The Phase 3 program of oral difelikefalin in patients with advanced CKD stages 4 or 5 with moderate-to-severe pruritus who are not on dialysis is ongoing. The Phase 3 program is comprised of two identical 12-week, double-blind, placebo-controlled studies, known as KICK 1 and KICK 2. The Company expects to report topline results in the second half of 2024.

 

Oral Difelikefalin: Atopic Dermatitis

 

The Phase 3 program for oral difelikefalin as an adjunctive therapy to topical corticosteroids in atopic dermatitis (AD) patients with moderate-to-severe pruritus is ongoing. The program is comprised of two studies, known as KIND 1 and KIND 2. Both studies are double-blind, controlled, 12-week studies with patients allowed to roll over to 52-week open-label safety extensions. At the end of the 12-week treatment period in Part A of KIND 1, the Company expects to have an internal data readout to inform the dose and sample size to initiate Part B and KIND 2. The internal readout is expected for the second half of 2023.

 

Oral Difelikefalin: Chronic Liver Disease-Associated Pruritus: Primary Biliary Cholangitis

 

The Company is currently conducting a proof-of-concept Phase 2 clinical trial of oral difelikefalin for the treatment of pruritus in patients with hepatic impairment due to primary biliary cholangitis (PBC). The trial is evaluating the safety and efficacy of oral difelikefalin versus placebo for 16 weeks. The Company expects to report topline data in the second half of 2022.

 

 

 

 

 

Upcoming Meeting Activities:

 

The Company expects to present at the following upcoming investment conferences:

 

·Canaccord Genuity 42nd Annual Growth Conference, August 8-11

 

·H.C. Wainwright 24th Annual Global Investment Conference, September 12-14

 

Second Quarter 2022 Financial Results

 

Cash, cash equivalents and marketable securities at June 30, 2022 totaled $204.7 million compared to $236.8 million at December 31, 2021. The decrease in the balance primarily resulted from $30.0 million of cash used in operating activities.

 

For the second quarter of 2022, net loss was $4.2 million, or $(0.08) per basic and diluted share, compared to net loss of $30.7 million, or ($0.61) per basic and diluted share, for the same period in 2021.

 

Revenues: Total revenue was $23.0 million for the three months ended June 30, 2022. There was no revenue during the same period of 2021. Revenue consisted of:

 

·$15.0 million of license and milestone fees revenue, related to the regulatory milestone payment for the approval of Kapruvia by the European Commission in April 2022 during the three months ended June 30, 2022; and

 

·$8.0 million of collaborative revenue, related to the profit-sharing revenue from Vifor’s sales of KORSUVA injection to third parties during the three months ended June 30, 2022.

 

Cost of Goods Sold (COGS): There was no COGS during the three months ended June 30, 2022 or June 30, 2021, as there was no commercial supply revenue recognized for the period.

 

Research and Development (R&D) Expenses: R&D expenses were $19.9 million for the three months ended June 30, 2022 compared to $25.2 million in the same period of 2021. The lower R&D expenses in 2022 were principally due to a $10.0 million milestone earned by Enteris during the three months ended June 30, 2021, partially offset by increases in direct clinical trial costs and related consultant costs during the three months ended June 30, 2022.

 

General and Administrative (G&A) Expenses: G&A expenses were $7.6 million for the three months ended June 30, 2022 compared to $5.7 million in the same period of 2021. The higher G&A expenses for the three months ended June 30, 2022 were principally due to increases in stock-based compensation expense, which included additional compensation expense relating to the modification of the Company’s former Chief Executive Officer’s equity awards in November 2021, as well as increases in accounting and auditing fees and payroll related costs.

 

 

 

 

 

Other Income, net: Other income, net was $0.3 million for the three months ended June 30, 2022 compared to $0.1 million in the same period of 2021. The increase in other income, net was primarily due to an increase in interest income resulting from a higher yield on the Company’s portfolio of investments during the three months ended June 30, 2022, partially offset by an increase in net amortization expense of available-for-sale securities during the three months ended June 30, 2022.

 

Financial Guidance

 

Based on timing expectations and projected costs for current clinical development plans, which include conducting supportive Phase 1 trials, Phase 2 trials in PBC and NP, and Phase 3 trials in CKD and AD, Cara expects that its current unrestricted cash and cash equivalents and available-for-sale marketable securities will be sufficient to fund its currently anticipated operating expenses and capital requirements into the first half of 2024, without giving effect to product revenue the Company receives from the commercialization of KORSUVA injection or Kapruvia or any potential milestone payments or potential additional product revenue the Company may receive under collaboration agreements.

 

About Cara Therapeutics

 

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed the placebo-controlled phase of a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

 

 

 

 

Forward-looking Statements

 

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the Company’s ability to successfully commercialize KORSUVA injection and Kapruvia, risks that KORSUVA injection and Kapruvia revenue, expenses and costs may not be as expected, planned future regulatory meetings and/or submissions and potential future regulatory approvals, the performance of the Company’s commercial partners, including Vifor, expected timing of the initiation, enrollment and data readouts from the Company’s planned and ongoing clinical trials, the potential results of ongoing clinical trials, timing of future regulatory and development milestones for the Company’s product candidates, the potential for the Company’s product candidates to be alternatives in the therapeutic areas investigated, including NP, and the potential for oral difelikefalin to address additional pruritic indications, the size and growth of the potential markets for pruritus management, the Company’s expected cash reach, and the potential impact of COVID-19, geopolitical tensions and macroeconomic conditions on the Company’s clinical development and regulatory timelines and plans. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Cara Therapeutics’ filings with the Securities and Exchange Commission, including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ending December 31, 2021 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission, including its Form 10-Q for the quarter ended June 30, 2022. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

Financial tables follow

 

 

 

 

CARA THERAPEUTICS, INC.
CONDENSED BALANCE SHEETS

(in thousands)

(unaudited)

 

   June 30,   December 31, 
   2022   2021 
Assets          
Current assets:          
Cash and cash equivalents  $46,718   $13,453 
Marketable securities   110,794    153,582 
Accounts receivable - related party   8,003    - 
Inventory, net   3,460    2,584 
Income tax receivable   697    697 
Other receivables   468    455 
Prepaid expenses   6,026    2,519 
Total current assets   176,166    173,290 
Operating lease right-of-use assets   2,278    2,973 
Marketable securities, non-current   47,171    69,754 
Property and equipment, net   549    631 
Restricted cash   408    408 
Total assets  $226,572   $247,056 
           
Liabilities and stockholders’ equity          
Current liabilities:          
Accounts payable and accrued expenses  $19,332   $15,861 
Operating lease liabilities, current   1,835    1,755 
Total current liabilities   21,167    17,616 
           
Operating lease liabilities, non-current   983    1,918 
           
Commitments and contingencies   -    - 
           
Stockholders’ equity:          
Preferred stock   -    - 
Common stock   53    53 
Additional paid-in capital   719,129    708,585 
Accumulated deficit   (512,713)   (480,758)
Accumulated other comprehensive loss   (2,047)   (358)
Total stockholders’ equity   204,422    227,522 
Total liabilities and stockholders’ equity  $226,572   $247,056 

 

 

 

 

 

CARA THERAPEUTICS, INC.
CONDENSED STATEMENTS OF OPERATIONS

(amounts in thousands, except share and per share data)

(unaudited)

 

   Three Months Ended June 30,   Six Months Ended June 30, 
   2022   2021   2022   2021 
Revenue:                
License and milestone fees  $15,000   $-   $15,000   $1,192 
Collaborative revenue   8,003    -    8,003    706 
Commercial supply revenue   -    -    4,790    - 
Clinical compound revenue   -    -    -    37 
Total revenue   23,003    -    27,793    1,935 
                     
Operating expenses:                    
Cost of goods sold   -    -    2,081    - 
Research and development   19,905    25,225    41,178    44,356 
General and administrative   7,570    5,651    16,917    12,016 
Total operating expenses   27,475    30,876    60,176    56,372 
Operating loss   (4,472)   (30,876)   (32,383)   (54,437)
                     
Other income, net   266    131    428    391 
Net loss   (4,206)   (30,745)   (31,955)   (54,046)
                     
Net loss per share:                    
Basic and Diluted  $(0.08)  $(0.61)  $(0.60)  $(1.08)
                     
Weighted average shares:                    
Basic and Diluted   53,614,668    50,059,984    53,561,161    49,989,379 

 

 

MEDIA CONTACT:

Annie Spinetta

6 Degrees

973-768-2170

aspinetta@6degreespr.com

 

INVESTOR CONTACT:

Iris Francesconi, Ph.D.

Cara Therapeutics

203-406-3700

investor@caratherapeutics.com

 

 

 

 EX-101.SCH 3 cara-20220808.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cara-20220808_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 cara-20220808_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2222475d2_ex99-1img001.jpg GRAPHIC begin 644 tm2222475d2_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Aug. 08, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 08, 2022
Entity File Number 001-36279
Entity Registrant Name CARA THERAPEUTICS, INC.
Entity Central Index Key 0001346830
Entity Tax Identification Number 75-3175693
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4 Stamford Plaza
Entity Address, Address Line Two 107 Elm Street
Entity Address, Address Line Three 9th Floor
Entity Address, City or Town Stamford
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06902
City Area Code 203
Local Phone Number 406-3700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol CARA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2222475d2_8k_htm.xml IDEA: XBRL DOCUMENT 0001346830 2022-08-08 2022-08-08 iso4217:USD shares iso4217:USD shares 0001346830 false 8-K 2022-08-08 CARA THERAPEUTICS, INC. DE 001-36279 75-3175693 4 Stamford Plaza 107 Elm Street 9th Floor Stamford CT 06902 203 406-3700 false false false false Common Stock, par value $0.001 per share CARA NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( &Z!"%4'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !N@0A5A#\C'NX K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2@,Q$(=?17+?G=T41<(V%\53"X(%Q5M(IFUP\X=D9+=O;W9MMX@^@)!+9G[Y MYAM(IZ/0(>%S"A$36H7-,!HM(? MZH# F^8.')(RBA1,P"HN1"8[HX5.J"BD,][H!1\_4S_#C ;LT:&G#&W= I/3 MQ'@:^PZN@ E&F%S^+J!9B'/U3^S< 79.CMDNJ6$8ZF$UY\H.+;QM-R_SNI7U MF9376%YE*^@4<SXXUH6\%OWR?7'WY781>,W=M_ M;'P1E!W\^A?R"U!+ P04 " !N@0A5F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M &Z!"%4G8!G_>@0 ,81 8 >&PO=V]R:W-H965T&UL MC9AM;^)&$,>_RLH]5:U$X@<(#RD@$4)ZZ.YR-' ]J55?+/:"5[%W?;OKD/33 MWZP!FU[-F#>);3Q__W9V_)^!X4ZJ9QTS9LAKF@@]"ASDW#!%HKH/$VI>KMC MB=R-'-\Y7GCBV]C8"^YXF-$M6S+S)5LH.'-+E8BG3&@N!5%L,W(F_NU=T+4! MQ1U_DA& A2+O;_Z>LA$: E+W@AH>PNWU8<"9LDF^OB==OD< +@O^& MNT!08@0E1E#HM3$,\O=DK8V"C?JGCFBOT*E7L-5[JS,:LI$#Y:F9>F'.^.>? M_*[W&\+7+OG:F/KX7H8YU*(AJ[>,U<'AX?VK#PA$IX3HH"H3((@*BH>$;NLH M\/@-331#.&Y*CIO+DK%@BLN(S$1$H/AJ\X(K%654U%%3(75+MBZJ.!.&FS?R MP!-&'O-T75_)F3U M?O8T6)*'B2NW>GV MVQZ"-2BQ!I=@K>@KF4? QC<\I(61G]]67+%W<]7V>S?=01O!\[W*.+U+ .B,@BH?]2C+.R?Q]U;YQSM9.UG+BD[_7(+$F!5D%SQ"BK M)N#C-HY3QO"<6DY<=&!B\',I%898M0@?]_@?$:?V#,IQ)7>B%@Z7.VXUQE:U M#1]W^Q_9RG=EH>0+%V%]]G#-Z0I#J[J&?U';*-$64ALPP[]X=OX%;F@BW8&' M-32_ZB!^@_479#!RGT?!!0(/=;RJ4?BXOW^4(>1D$4N!]=8&D8[7O6KW/*Q% M^%6/\'%+_ZJX,4Q 8M(T%X<&H6NI<*&FT2BHVD* &_=2)CSDAHLM^03EK3A- M:H=97*61I^H 6[7"\6N0D@/@_=K/\'"$ FS]N?-IG[_&O0:R4Y&?MR@_TROOAP 3MK8B25 MX0>X.1\S1F:O84S%EIT=?AN$'B?+^\D?&%/E],%%3C]+F=K:+/T."M"!88' M,:/P+M@;X/.-E.9X8K_[ES_=C+\#4$L#!!0 ( &Z!"%6?H!OPL0( .(, M - >&PO9KEMWDOSAR+DCO9*Z MW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MU MIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$ M>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5 M=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T M08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+ M?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!. MZ%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^& M^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA M>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7J MEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N- MY0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( &Z! M"%67BKL

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://caratherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2222475d2_8k.htm cara-20220808.xsd cara-20220808_lab.xml cara-20220808_pre.xml tm2222475d2_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2222475d2_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2222475d2_8k.htm" ] }, "labelLink": { "local": [ "cara-20220808_lab.xml" ] }, "presentationLink": { "local": [ "cara-20220808_pre.xml" ] }, "schema": { "local": [ "cara-20220808.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "CARA", "nsuri": "http://caratherapeutics.com/20220808", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2222475d2_8k.htm", "contextRef": "From2022-08-08to2022-08-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://caratherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2222475d2_8k.htm", "contextRef": "From2022-08-08to2022-08-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://caratherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001104659-22-087229-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-087229-xbrl.zip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